The purpose of this systematic review and meta-analysis is to update the side effect profile of ALK inhibitors in NSCLC with a focus in select adverse events, considering the recent approvals and very recent publication of full manuscripts of respective clinical trials. The gene discussed is ALK; the disease is non-small cell lung carcinoma.